Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

Sarepta is the first company to publicly disclose that it's received the designation, for which the FDA had issued a draft guidance last year.

The study adds to growing evidence that digital tools can maximize genetic counselors' limited time without patient harm.

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...